Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma
Background: Aggressive pancreatobiliary tumors often require oxaliplatin-based therapies, instead of standard gemcitabine-based therapy and biomarker studies at diagnosis to decide the appropriate therapeutic regimen. The ribonucleotide Reductase catalytic subunit M1 (RRM1) and excision repair cross...
Guardado en:
Autores principales: | , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wolters Kluwer Medknow Publications
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0308f19bce6a47979b52fb9fb0ccd539 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0308f19bce6a47979b52fb9fb0ccd539 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0308f19bce6a47979b52fb9fb0ccd5392021-12-02T17:28:22ZExpression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma0377-492910.4103/IJPM.IJPM_537_19https://doaj.org/article/0308f19bce6a47979b52fb9fb0ccd5392021-01-01T00:00:00Zhttp://www.ijpmonline.org/article.asp?issn=0377-4929;year=2021;volume=64;issue=5;spage=160;epage=165;aulast=Khetanhttps://doaj.org/toc/0377-4929Background: Aggressive pancreatobiliary tumors often require oxaliplatin-based therapies, instead of standard gemcitabine-based therapy and biomarker studies at diagnosis to decide the appropriate therapeutic regimen. The ribonucleotide Reductase catalytic subunit M1 (RRM1) and excision repair cross-complementing gene-1 (ERCC1) are related to DNA synthesis and repair and essential in this regard. However, apart from the therapeutic benefit, their prognostic implication is controversial. Methods: In this retrospective study, paraffin-embedded tissue from 51 cases of pancreatic cancer and 29 cases of cholangiocarcinoma were evaluated for RRM1 and ERCC1 expression by immunohistochemical technique along with 18 control pancreatic and biliary tissues. The semiquantitatively H score was calculated based on stain distribution and stain intensities. Results: Both RRM1 and ERCC1 expression were high in tumor epithelium than in controls (RRM1: the difference was statistically significant in cholangiocarcinoma (P = 0.008); ERCC1: the difference was statistically significant both in pancreatic and cholangiocarcinoma (P < 0.05)]. However, no correlation was noted between RRM1 and ERCC1-low and high tumors with histological markers of prognosis and overall survival in these patients. Conclusions: The present study adds further evidence against the controversy that if RRM1 and ERCC1 expression in pancreatic and biliary carcinomas have any prognostic significance apart from their proven therapeutic benefits in these tumors.Khushbu KhetanRanjit K SahooVandana BalodaShalimarSreenivas VishnubhatlaAnoop SarayaNihar Ranjan DashAtul SharmaSiddhartha DattaGuptaPrasenjit DasWolters Kluwer Medknow Publicationsarticlecholangiocarcinomaexcision repair cross-complementing gene-1pancreatic adenocarcinomaprognosisribonucleotide reductase catalytic subunit m1PathologyRB1-214MicrobiologyQR1-502ENIndian Journal of Pathology and Microbiology, Vol 64, Iss 5, Pp 160-165 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
cholangiocarcinoma excision repair cross-complementing gene-1 pancreatic adenocarcinoma prognosis ribonucleotide reductase catalytic subunit m1 Pathology RB1-214 Microbiology QR1-502 |
spellingShingle |
cholangiocarcinoma excision repair cross-complementing gene-1 pancreatic adenocarcinoma prognosis ribonucleotide reductase catalytic subunit m1 Pathology RB1-214 Microbiology QR1-502 Khushbu Khetan Ranjit K Sahoo Vandana Baloda Shalimar Sreenivas Vishnubhatla Anoop Saraya Nihar Ranjan Dash Atul Sharma Siddhartha DattaGupta Prasenjit Das Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
description |
Background: Aggressive pancreatobiliary tumors often require oxaliplatin-based therapies, instead of standard gemcitabine-based therapy and biomarker studies at diagnosis to decide the appropriate therapeutic regimen. The ribonucleotide Reductase catalytic subunit M1 (RRM1) and excision repair cross-complementing gene-1 (ERCC1) are related to DNA synthesis and repair and essential in this regard. However, apart from the therapeutic benefit, their prognostic implication is controversial. Methods: In this retrospective study, paraffin-embedded tissue from 51 cases of pancreatic cancer and 29 cases of cholangiocarcinoma were evaluated for RRM1 and ERCC1 expression by immunohistochemical technique along with 18 control pancreatic and biliary tissues. The semiquantitatively H score was calculated based on stain distribution and stain intensities. Results: Both RRM1 and ERCC1 expression were high in tumor epithelium than in controls (RRM1: the difference was statistically significant in cholangiocarcinoma (P = 0.008); ERCC1: the difference was statistically significant both in pancreatic and cholangiocarcinoma (P < 0.05)]. However, no correlation was noted between RRM1 and ERCC1-low and high tumors with histological markers of prognosis and overall survival in these patients. Conclusions: The present study adds further evidence against the controversy that if RRM1 and ERCC1 expression in pancreatic and biliary carcinomas have any prognostic significance apart from their proven therapeutic benefits in these tumors. |
format |
article |
author |
Khushbu Khetan Ranjit K Sahoo Vandana Baloda Shalimar Sreenivas Vishnubhatla Anoop Saraya Nihar Ranjan Dash Atul Sharma Siddhartha DattaGupta Prasenjit Das |
author_facet |
Khushbu Khetan Ranjit K Sahoo Vandana Baloda Shalimar Sreenivas Vishnubhatla Anoop Saraya Nihar Ranjan Dash Atul Sharma Siddhartha DattaGupta Prasenjit Das |
author_sort |
Khushbu Khetan |
title |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
title_short |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
title_full |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
title_fullStr |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
title_full_unstemmed |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma |
title_sort |
expression patterns and prognostic significances of rrm1 and ercc1 in pancreatic carcinoma and cholangiocarcinoma |
publisher |
Wolters Kluwer Medknow Publications |
publishDate |
2021 |
url |
https://doaj.org/article/0308f19bce6a47979b52fb9fb0ccd539 |
work_keys_str_mv |
AT khushbukhetan expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT ranjitksahoo expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT vandanabaloda expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT shalimar expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT sreenivasvishnubhatla expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT anoopsaraya expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT niharranjandash expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT atulsharma expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT siddharthadattagupta expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma AT prasenjitdas expressionpatternsandprognosticsignificancesofrrm1andercc1inpancreaticcarcinomaandcholangiocarcinoma |
_version_ |
1718380712844853248 |